Race Oncology Ltd has released a press release.
Appendix 4E & Annual Financial Statements
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Issue of Options
- Peer-Reviewed The Rediscovery of Bisantrene Published
- Race Completes Over-Subscribed $2.5 Million Placement
- Race Joint Venture with TargImmune
- Race Announces NCI Collaboration
Later from Racura Oncology
- Race Oncology Produces First Batch of Bisantrene
- Race Receives $170k R&D Tax Incentive Refund
- Notice of Allowance for Bisantrene Patent in US
- Second Bisantrene Patent Allowed in US
- Race completes over-subscribed $3.159 million placement
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology